Literature DB >> 25751200

Sociodemographic disparities in advanced ovarian cancer survival and adherence to treatment guidelines.

Robert E Bristow1, Jenny Chang, Argyrios Ziogas, Belinda Campos, Leo R Chavez, Hoda Anton-Culver.   

Abstract

OBJECTIVE: To estimate whether race or ethnic and socioeconomic strata are independently associated with advanced-stage ovarian cancer-specific survival after adjusting for adherence to National Comprehensive Cancer Network treatment guidelines.
METHODS: The design was a retrospective population-based cohort study of patients with stage IIIC-IV epithelial ovarian cancer identified from the Surveillance, Epidemiology, and End Results-Medicare database (1992-2009). Quartile of census tract median household income was used as the measure of socioeconomic status (quartiles 1-4). A multivariable logistic regression model was used to identify characteristics predictive of adherence to National Comprehensive Cancer Network guidelines for surgery and chemotherapy. Cox proportional hazards models and propensity score matching were used for survival analyses.
RESULTS: A total of 10,296 patients were identified, and 30.2% received National Comprehensive Cancer Network guideline-adherent care. Among demographic variables, black race (adjusted odds ratio [OR] 1.53, 95% confidence interval [CI] 1.22-1.92) and low socioeconomic status (quartile 1, adjusted OR 1.32, 95% CI 1.14-1.52) were independently associated with nonguideline care. Stratified multivariate survival analysis using the propensity score-matched sample (n=5,124) revealed that deviation from treatment guidelines was associated with a comparable risk of disease-related death across race-ethnicity: whites (adjusted hazard ratio [HR] 1.59, 95% CI 1.48-1.71), blacks (adjusted HR 1.66, 95% CI 1.19-2.30), Asian or Pacific Islanders (adjusted HR 1.52, 95% CI 0.99-1.92), and Hispanics (adjusted HR 1.91, 95% CI 0.98-3.72). Across socioeconomic status, deviation from treatment guidelines was also associated with a comparable risk of ovarian cancer mortality for quartile 1 (adjusted HR 1.69, 95% CI 1.47-1.95), quartile 2 (adjusted HR 1.63, 95% CI 1.42-1.87), quartile 3 (adjusted HR 1.51, 95% CI 1.32-1.73), and quartile 4 (adjusted HR 1.57, 95% CI 1.38-1.79).
CONCLUSION: Adherence to treatment guidelines for advanced-stage ovarian cancer is associated with equivalent survival benefit across racial or ethnic and socioeconomic strata. Ensuring equal access to standard treatment is a viable strategic approach to reduce survival disparities.

Entities:  

Mesh:

Year:  2015        PMID: 25751200      PMCID: PMC5167570          DOI: 10.1097/AOG.0000000000000643

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  29 in total

1.  AACR Cancer Progress Report 2015.

Authors:  José Baselga; Nina Bhardwaj; Lewis C Cantley; Ronald DeMatteo; Raymond N DuBois; Margaret Foti; Susan M Gapstur; William C Hahn; Lee J Helman; Roy A Jensen; Electra D Paskett; Theodore S Lawrence; Stuart G Lutzker; Eva Szabo
Journal:  Clin Cancer Res       Date:  2015-10-01       Impact factor: 12.531

2.  Racial and socioeconomic disparities in adherence to preventive health services for ovarian cancer survivors.

Authors:  Lacey Loomer; Kevin C Ward; Evelyn A Reynolds; Silke A von Esenwein; Joseph Lipscomb
Journal:  J Cancer Surviv       Date:  2019-06-06       Impact factor: 4.442

3.  ASO Author Reflections: Disparities in Access to Cytoreductive Surgery.

Authors:  Ellen M Goldberg; Oliver S Eng
Journal:  Ann Surg Oncol       Date:  2021-05-19       Impact factor: 5.344

4.  Recent Trends in Ovarian Cancer Incidence and Relative Survival in the United States by Race/Ethnicity and Histologic Subtypes.

Authors:  Hyo K Park; Julie J Ruterbusch; Michele L Cote
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-07-27       Impact factor: 4.254

5.  Demographic, presentation, and treatment factors and racial disparities in ovarian cancer hospitalization outcomes.

Authors:  Tomi F Akinyemiju; Gurudatta Naik; Kemi Ogunsina; Daniel T Dibaba; Neomi Vin-Raviv
Journal:  Cancer Causes Control       Date:  2018-02-10       Impact factor: 2.506

6.  Disparities in ovarian cancer survival in the United States (2001-2009): Findings from the CONCORD-2 study.

Authors:  Sherri L Stewart; Rhea Harewood; Melissa Matz; Sun Hee Rim; Susan A Sabatino; Kevin C Ward; Hannah K Weir
Journal:  Cancer       Date:  2017-12-15       Impact factor: 6.860

7.  Contribution of Geographic Location to Disparities in Ovarian Cancer Treatment.

Authors:  Carolina Villanueva; Jenny Chang; Scott M Bartell; Argyrios Ziogas; Robert Bristow; Verónica M Vieira
Journal:  J Natl Compr Canc Netw       Date:  2019-11-01       Impact factor: 11.908

8.  Trends and factors associated with radical cytoreductive surgery in the United States: A case for centralized care.

Authors:  A K Sinno; X Li; R E Thompson; E J Tanner; K L Levinson; R L Stone; S M Temkin; A N Fader; D S Chi; K Long Roche
Journal:  Gynecol Oncol       Date:  2017-03-30       Impact factor: 5.482

9.  Choosing Wisely: Opportunities for Improving Value in Cancer Care Delivery?

Authors:  Gabrielle B Rocque; Courtney P Williams; Bradford E Jackson; Audrey S Wallace; Karina I Halilova; Kelly M Kenzik; Edward E Partridge; Maria Pisu
Journal:  J Oncol Pract       Date:  2016-11-15       Impact factor: 3.840

10.  Socio-economic disparities in long-term cancer survival-10 year follow-up with individual patient data.

Authors:  Susanne Singer; Michael Bartels; Susanne Briest; Jens Einenkel; Dietger Niederwieser; Kirsten Papsdorf; Jens-Uwe Stolzenburg; Sophie Künstler; Sabine Taubenheim; Oliver Krauß
Journal:  Support Care Cancer       Date:  2016-12-10       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.